Singapore markets close in 7 hours 35 minutes

Fulcrum Therapeutics, Inc. (FULC)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
7.15-0.26 (-3.51%)
At close: 04:00PM EDT
7.15 0.00 (0.00%)
After hours: 04:20PM EDT
Full screen
Loading interactive chart…
  • GlobeNewswire

    Fulcrum Therapeutics to Participate at the Cantor Virtual Muscular Dystrophy Symposium

    CAMBRIDGE, Mass., March 28, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that management will participate in a fireside chat at the Cantor Virtual Muscular Dystrophy Symposium, being held on Tuesday, April 2, 2024 at 10:40 a.m. ET. The webcast of the presentation will be accessible here an

  • GlobeNewswire

    Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    CAMBRIDGE, Mass., March 22, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that the company granted non-statutory stock options to Patrick Horn, M.D., Ph.D., the company’s newly appointed chief medical officer. Fulcrum granted stock options to purchase shares of the company’s common stock pursuant to the co

  • GlobeNewswire

    Fulcrum Therapeutics Appoints Patrick Horn M.D., Ph.D., as Chief Medical Officer

    ―Industry veteran with late-stage clinical development, medical affairs, and regulatory experience; well-positioned to advance losmapimod towards a potential regulatory submission and approval ― ― Interim Chief Medical Officer, Iain Fraser, MBChB, DPhil, will continue to serve on Fulcrum’s executive leadership team as senior vice president (SVP) of early development ― CAMBRIDGE, Mass., March 18, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Fulcrum) (Nasdaq: FULC), a clinical-stage bioph